News zum Sektor Gesundheit aus Island

 

Announcement no. 44/2026 7 September 2026 Reykjavik, Iceland/Copenhagen, Denmark, 7 September 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 37/2025 dated 17 July 2026. During the period 24 August to 4 September 2026 Embla Medical has acquired 94,630 shares under the Program at the average price of DKK 29.41. Following the transactions below, the Company holds 2,605,231 shares, corresponding to 0.61% of the...

Embla Medical bündelt sein breiteres Geschäft unter einem neuen Konzernnamen. Össur bleibt als Premiummarke für Prothetik und Orthesen erhalten. Formotion vereint das Klinikgeschäft. "Embla wandelt sich vom Prothesenhersteller zur globalen Mobilitätsgruppe", sagt IR-Chef Klaus Sindahl. Der Umsatz soll 2026 erstmals eine Milliarde US-Dollar überschreiten. Der Prothetikmarkt wächst jährlich um 6 bis 8 %. Embla investiert 7 bis 8 % des Umsatzes in Forschung. Das entspricht mehr als 50 Mio. Euro. Das Produktgeschäft wuchs zuletzt um 12 %. Patient Care verlor dagegen 2 %. Sindahl erklärt den Rückgang mit der Klinikintegration und Einzelereignissen in Schweden und Frankreich. "Wir erwarten in den kommenden Quartalen wieder Wachstum." Fast 200 Kliniken schaffen direkten Zugang zu Patienten. Im Markt sieht Sindahl zwei große, voll integrierte Anbieter. "Ottobock und wir sind seit vielen Jahren direkte Konkurrenten." Embla positioniert sich als klare Nummer zwei. Die Bilanz erlaubt laut Sindahl weiter...

Announcement no. 43/2026 24 August 2026 Reykjavik, Iceland/Copenhagen, Denmark, 24 August 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 37/2025 dated 17 July 2026. During the period 17 August to 21 August 2026 Embla Medical has acquired 56,000 shares under the Program at the average price of DKK 29.71. Following the transactions below, the Company holds 2,510,601 shares, corresponding to 0.59% of the...

Announcement no. 42/2026 17 August 2026 Reykjavik, Iceland/Copenhagen, Denmark, 17 August 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 37/2025 dated 17 July 2026. During the period 10 August to 14 August 2026 Embla Medical has acquired 50,246 shares under the Program at the average price of DKK 29.68. Following the transactions below, the Company holds 2,454,601 shares, corresponding to 0.57% of the...

Announcement no. 41/2026 10 August 2026 Reykjavik, Iceland/Copenhagen, Denmark, 10 August 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 37/2025 dated 17 July 2026. During the period 3 August to 7 August  2026 Embla Medical has acquired 55,654 shares under the Program at the average price of DKK 28.91. Following the transactions below, the Company holds 2,404,355 shares, corresponding to 0.56% of the...

Announcement no. 40/2026 3 August 2026 Reykjavik, Iceland/Copenhagen, Denmark, 3 August 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 37/2025 dated 17 July 2026. During the period 27 July to 31 July 2026 Embla Medical has acquired 47,000 shares under the Program at the average price of DKK 28.35. Following the transactions below, the Company holds 2,348,701 shares, corresponding to 0.55% of the Company's...

· The Nordic Investment Bank (NIB) has signed a EUR 50 million 7-year loan with Embla Medical hf.  · The financing will support the company's research and development activities during 2027–2029.  · The project contributes to innovation in the healthcare sector and the development of advanced medical technologies.   The investments focus on the development of new and improved prosthetics, orthotics and related healthcare solutions, including advances in materials, digital technologies and patient care.  “Innovation in medical technology plays an important role in improving quality...

Announcement no. 39/2026 28 July 2026 Reykjavik, Iceland/Copenhagen, Denmark, 28 July 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 37/2025 dated 17 July 2026. During the period 20 July to 24 July 2026 Embla Medical has acquired 66,500 shares under the Program at the average price of DKK 26.95. Following the transactions below, the Company holds 2,301,701 shares, corresponding to 0.54% of the Company's...

Announcement no. 38/2026 Interim Report Q2 2026 Sveinn Sölvason, President and CEO, comments: “Sales in Q2 2026 were USD 259 million, representing 11% reported growth and 6% organic growth. Strong double-digit Prosthetics & Neuro Orthotics growth in Q2, supported by excellent execution, robust volume growth in EMEA and APAC, and successful new product launches. Bracing & Supports delivered moderate growth in the quarter, while Patient Care declined. In Patient Care, we continue to see encouraging progress, with most of our clinics delivering increased productivity and...

Announcement no. 37/2026 17 July 2026 Reykjavik, Iceland/Copenhagen, Denmark, 17 July 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced that the Company has decided to initiate a new share buyback program (the “Program”) on Monday, 20 July 2026. The Program will be carried out in accordance with Regulation No. 596/2014 of the European Parliament and of the Council on market abuse ("MAR"), and the Commission's delegated regulation 2016/1052. The purpose of the Program is to reduce the Company's share capital...

Announcement no. 36/2026 17 July 2026 Reykjavik, Iceland/Copenhagen, Denmark, 17 July 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced the completion of the share buyback program, which was announced in Company Announcement no. 3/2025 dated 7 February 2025. Following are the last transactions carried out under the current share buyback program. Transaction No. of Avg. purchase price in DKK Transaction value in DKK date shares 13 July 10,000 26.47...

Announcement no. 35/2026 13 July 2026 Reykjavik, Iceland/Copenhagen, Denmark, 13 July 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 6 July  to 10 July 2026 Embla Medical has acquired 50,106 shares under the Program at the average price of DKK 26.81. Following the transactions below, the Company holds 2,195,201 shares, corresponding to 0.52% of the Company's...

Reykjavik, Iceland/Copenhagen, Denmark, 7 July 2026. Embla Medical (Nasdaq Copenhagen: EMBLA) will publish its Q2 2026 Report on July 21, 2026, at 7:00 CET. A conference call will be hosted on the same day at 9:00 CET / 7:00 GMT / 3:00am EST. The event will be hosted by Sveinn Solvason, President and CEO, and G. Arna Sveinsdottir, CFO. The call will include a review of the quarterly results and will be held in English. Slides used in the presentation will be made available on the company website at the following link: https://www.emblamedical.com/investors To participate in the...

Announcement no. 34/2026 6 July 2026 Reykjavik, Iceland/Copenhagen, Denmark, 6 July 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 29 June to 3 July 2026 Embla Medical has acquired 57,000 shares under the Program at the average price of DKK 26.95. Following the transactions below, the Company holds 2,145,095 shares, corresponding to 0.50% of the Company's...

Announcement no. 33/2026 29 June 2026 Reykjavik, Iceland/Copenhagen, Denmark, 29 June 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 22 June to 26 June 2026 Embla Medical has acquired 113,000 shares under the Program at the average price of DKK 25.96. Following the transactions below, the Company holds 2,088,095 shares, corresponding to 0.49% of the Company'...

Announcement no. 32/2026 22 June 2026 Reykjavik, Iceland/Copenhagen, Denmark, 22 June 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 15 June to 19 June 2026 Embla Medical has acquired 125,000 shares under the Program at the average price of DKK 26.89. Following the transactions below, the Company holds 1,975,095 shares, corresponding to 0.46% of the Company'...

Announcement no. 31/2026 15 June 2026 Reykjavik, Iceland/Copenhagen, Denmark, 15 June 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 8 June to 12 June 2026 Embla Medical has acquired 107,000 shares under the Program at the average price of DKK 26.91. Following the transactions below, the Company holds 1,850,095 shares, corresponding to 0.43% of the Company's...

Announcement no. 30/2026 8 June 2026 Reykjavik, Iceland/Copenhagen, Denmark, 8 June 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 1 June to 4 June 2026 Embla Medical has acquired 58,784 shares under the Program at the average price of DKK 26.98. Following the transactions below, the Company holds 1,743,095 shares, corresponding to 0.41% of the Company's...

Announcement no. 29/2026 1 June 2026 Reykjavik, Iceland/Copenhagen, Denmark, 1 June 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 26 May to 29 May 2026 Embla Medical has acquired 83,854 shares under the Program at the average price of DKK 27.04. Following the transactions below, the Company holds 1,684,311 shares, corresponding to 0.40% of the Company's...

Announcement no. 28/2026 26 May 2026 Reykjavik, Iceland/Copenhagen, Denmark, 26 May 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 18 May to 22 May 2026 Embla Medical has acquired 108,000 shares under the Program at the average price of DKK 26.32. Following the transactions below, the Company holds 1,600,457 shares, corresponding to 0.38% of the Company's...